Scientific Sessions 2024  /  Obesity and HFpEF: From Mechanisms to Management  /  Multisystem pathology of HFpEF in obesity
Logo

American Heart Association

  111
  0

Final ID:

Multisystem pathology of HFpEF in obesity

  • Shah, Sanjiv  ( NORTHWESTERN UNIVERSITY , Chicago , Illinois , United States )
  • Lewis, Gregory  ( MGH , Boston , Massachusetts , United States )
  • Sauer, Andrew  ( Saint Lukes Mid America Heart Inst , Kansas City , Missouri , United States )
    • Author Disclosures:
    Sanjiv Shah: DO have relevant financial relationships ; Consultant:Bayer:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Axon Therapies:Active (exists now) ; Consultant:Corvia :Active (exists now) ; Consultant:Boehringer-Ingelheim:Active (exists now) ; Consultant:Bristol-Myers Squibb:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Tenax:Active (exists now) ; Consultant:Intellia:Active (exists now) ; Consultant:Rivus:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Pfizer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) | Gregory Lewis: DO have relevant financial relationships ; Research Funding (PI or named investigator):National Institutes of Health (R01-HL 151841, R01-HL131029, and R01-HL159514); Amgen; Cytokinetics; Applied Therapeutics; AstraZeneca; Imbria; Rivus; SoniVie; Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Rivus:Active (exists now) ; Research Funding (PI or named investigator):Astra Zeneca:Past (completed) ; Advisor:Ask Bio:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Applied Therapeutics:Past (completed) ; Consultant:Edwards:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now) ; Research Funding (PI or named investigator):Americal Heart Associiation:Active (exists now) | Andrew Sauer: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Researcher:35 Pharma:Active (exists now) ; Researcher:RIVUS:Active (exists now) ; Researcher:Astra Zeneca:Active (exists now) ; Researcher:CSL Vifor:Active (exists now) ; Researcher:Bayer:Active (exists now) ; Individual Stocks/Stock Options:ISHI:Active (exists now) ; Consultant:Story Health:Active (exists now) ; Consultant:General Prognostics:Active (exists now) ; Consultant:Acorai:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Impulse Dynamics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Obesity and HFpEF: From Mechanisms to Management

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Case presentation

Ozkan Bige, Keshvani Neil

The diagnostic approach to HFpEF in obesity

Sarma Satyam, Sharma Kavita

More abstracts from these authors:
Discussant

Sauer Andrew


Revolutionizing the Electronic Medical Record to Optimize GDMT

Sauer Andrew, Morris Alanna

You have to be authorized to contact abstract author. Please, Login
Not Available